← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

IDEAYA Biosciences, Inc. (IDYA) 10-Year Financial Performance & Capital Metrics

IDYA •
HealthcareBiotechnologyOncology Therapeutics Developers
AboutIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more
  • Revenue $219M +3024.4%
  • EBITDA -$155M +52.1%
  • Net Income -$114M +58.6%
  • EPS (Diluted) -1.28 +61.9%
  • Gross Margin 97.9% +116.5%
  • EBITDA Margin -70.74% +98.5%
  • Operating Margin -72.84% +98.4%
  • Net Margin -51.99% +98.7%
  • ROE -10.92% +66.6%
  • ROIC -12.37% +63.2%
  • Debt/Equity 0.03 +50.8%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 62.1%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y62.11%
3Y62.54%
TTM3024.43%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM58.58%

EPS CAGR

10Y-
5Y-
3Y-
TTM60.3%

ROCE

10Y Avg-38.29%
5Y Avg-23.17%
3Y Avg-26.97%
Latest-14.97%

Peer Comparison

Oncology Therapeutics Developers
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
EXELExelixis, Inc.11.81B44.0615.856.98%29.63%31.37%7.49%0.08
INCYIncyte Corporation20.1B101.2715.8021.22%25.03%24.9%6.74%0.01
GMABGenmab A/S18.13B29.4415.3630.67%46.8%114.25%6.6%0.03
SNDXSyndax Pharmaceuticals, Inc.1.89B21.71-5.82-279.31%-269.93%1.20
RCUSArcus Biosciences, Inc.2.55B20.37-6.19-4.26%-142.91%-55.94%0.16
RLAYRelay Therapeutics, Inc.1.78B10.26-6.3753.44%-18.01%-48.76%0.06
STROSutro Biopharma, Inc.1.74B20.47-6.92-59.64%-205.18%-234.19%4.57
OLMAOlema Pharmaceuticals, Inc.1.66B24.20-11-48.77%0.00

Compare IDYA vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs RVMD

Compare head-to-head with Revolution Medicines, Inc.

vs INCY

Compare head-to-head with Incyte Corporation

Compare Top 5

vs RVMD, INCY, GMAB, EXEL

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+00019.54M27.94M50.93M23.39M7M218.71M
Revenue Growth %----43.01%82.28%-54.08%-70.07%3024.43%
Cost of Goods Sold+391K886K1.25M1.38M1.73M2.1M4.01M3.83M4.59M
COGS % of Revenue---7.07%6.17%4.13%17.14%54.77%2.1%
Gross Profit+-391K-886K-1.25M18.16M26.22M48.83M19.38M3.17M214.12M
Gross Margin %---92.93%93.83%95.87%82.86%45.23%97.9%
Gross Profit Growth %--126.6%-40.52%1558.39%44.39%86.26%-60.32%-83.66%6663.01%
Operating Expenses+14.05M35.53M43.03M53.5M76.48M111.33M153.81M330.14M373.43M
OpEx % of Revenue---273.83%273.73%218.59%657.71%4716.3%170.74%
Selling, General & Admin1.66M3.78M8.71M13.8M18.33M21.8M24.3M35.47M63.32M
SG&A % of Revenue---70.65%65.59%42.8%103.9%506.69%28.95%
Research & Development12.38M31.75M34.32M39.7M58.16M89.54M129.51M294.67M314.7M
R&D % of Revenue---203.18%208.15%175.8%553.81%4209.61%143.89%
Other Operating Expenses00000000-4.59M
Operating Income+-14.44M-36.42M-44.27M-35.34M-50.27M-62.5M-134.43M-326.98M-159.31M
Operating Margin %----180.9%-179.91%-122.72%-574.85%-4671.07%-72.84%
Operating Income Growth %--152.23%-21.57%20.16%-42.23%-24.34%-115.08%-143.23%51.28%
EBITDA+-14.05M-35.53M-43.03M-33.96M-48.54M-60.4M-130.42M-323.14M-154.72M
EBITDA Margin %----173.83%-173.73%-118.59%-557.71%-4616.3%-70.74%
EBITDA Growth %--152.94%-21.09%21.06%-42.93%-24.43%-115.93%-147.77%52.12%
D&A (Non-Cash Add-back)391K886K1.25M1.38M1.73M2.1M4.01M3.83M4.59M
EBIT-11.86M-34.35M-41.98M-34.49M-49.76M-58.66M-112.96M-274.48M-159.31M
Net Interest Income+150K1.99M2.29M849K506K3.85M21.47M52.5M45.62M
Interest Income150K1.99M2.29M849K506K3.85M21.47M52.5M45.62M
Interest Expense000000000
Other Income/Expense2.58M2.07M2.3M849K506K3.85M21.47M52.5M45.62M
Pretax Income+-11.86M-34.35M-41.98M-34.49M-49.76M-58.66M-112.96M-274.48M-113.7M
Pretax Margin %----176.55%-178.1%-115.17%-483.05%-3921.1%-51.99%
Income Tax+000000000
Effective Tax Rate %100%100%100%100%100%100%100%100%100%
Net Income+-11.86M-34.35M-41.98M-34.49M-49.76M-58.66M-112.96M-274.48M-113.7M
Net Margin %----176.55%-178.1%-115.17%-483.05%-3921.1%-51.99%
Net Income Growth %--189.55%-22.21%17.82%-44.26%-17.87%-92.59%-142.98%58.58%
Net Income (Continuing)-11.86M-34.35M-41.98M-34.49M-49.76M-58.66M-112.96M-274.48M-113.7M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-0.83-2.41-1.90-1.31-1.41-1.42-1.96-3.36-1.28
EPS Growth %--190.36%21.16%31.05%-7.63%-0.71%-38.03%-71.43%61.9%
EPS (Basic)-0.83-2.41-1.90-1.31-1.41-1.42-1.96-3.36-1.28
Diluted Shares Outstanding14.24M14.24M20.23M24.72M35.25M41.44M57.52M81.68M88.49M
Basic Shares Outstanding14.24M14.24M20.23M24.72M35.25M41.44M57.52M81.68M88.49M
Dividend Payout Ratio---------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+13.58M90.67M101.65M288.61M251M370.45M532.63M689.71M666.73M
Cash & Short-Term Investments13.16M89.96M98.96M283.58M246.77M364.83M525.11M676.32M639.39M
Cash Only5.96M20.5M34.07M72.04M92.05M68.63M157.02M84.38M112.83M
Short-Term Investments7.2M69.46M64.89M211.55M154.72M296.2M368.1M591.94M526.56M
Accounts Receivable0001.88M1.1M211K18K3K0
Days Sales Outstanding---35.0714.411.510.280.16-
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets000005.41M7.5M13.39M27.34M
Total Non-Current Assets+3.9M5.87M11.35M9.66M130.35M17.52M116.68M434.38M442.6M
Property, Plant & Equipment3.74M5.15M9.7M9.48M8.66M8.99M8.41M27.74M31.29M
Fixed Asset Turnover---2.06x3.23x5.66x2.78x0.25x6.99x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments71K01.53M0121.29M8.32M107.49M405.83M0
Other Non-Current Assets89K722K122K188K397K205K782K805K411.31M
Total Assets+17.48M96.54M113M298.27M381.35M387.97M649.32M1.12B1.11B
Asset Turnover---0.07x0.07x0.13x0.04x0.01x0.20x
Asset Growth %-452.33%17.05%163.95%27.85%1.74%67.36%73.12%-1.31%
Total Current Liabilities+2.43M5.41M6.94M38.64M45.16M31.72M27.1M46.07M58.81M
Accounts Payable662K1.42M709K953K2.1M4.28M6.6M15.42M17.58M
Days Payables Outstanding617.98583.75207.86251.88444.35743.55600.871.47K1.4K
Short-Term Debt00000000339K
Deferred Revenue (Current)297K0027.61M29.04M8.57M000
Other Current Liabilities728K413K63K18K0011.78M30.35M40.89M
Current Ratio5.58x16.75x14.65x7.47x5.56x11.68x19.65x14.97x11.34x
Quick Ratio5.58x16.75x14.65x7.47x5.56x11.68x19.65x14.97x11.34x
Cash Conversion Cycle---------
Total Non-Current Liabilities+30.78M140.08M5.66M61.35M34.67M6.8M1.13M18.87M27.57M
Long-Term Debt3.21M000000027.57M
Capital Lease Obligations005.63M5.18M3.48M1.61M1.13M18.87M0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities27.58M140.08M34K12K00000
Total Liabilities33.22M145.49M12.6M100M79.83M38.51M28.23M64.94M86.39M
Total Debt+3.21M06.77M6.72M5.18M3.48M2.87M19.17M27.91M
Net Debt-2.75M-20.5M-27.3M-65.31M-86.86M-65.15M-154.15M-65.21M-84.91M
Debt / Equity--0.07x0.03x0.02x0.01x0.00x0.02x0.03x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage---------
Total Equity+-15.74M-48.95M100.4M198.27M301.51M349.45M621.09M1.06B1.02B
Equity Growth %--211%305.12%97.48%52.07%15.9%77.73%70.53%-3.42%
Book Value per Share-1.11-3.444.968.028.558.4310.8012.9711.56
Total Shareholders' Equity-15.74M-48.95M100.4M198.27M301.51M349.45M621.09M1.06B1.02B
Common Stock1K02K3K4K5K7K9K9K
Retained Earnings-16.17M-50.52M-92.49M-126.99M-176.75M-235.4M-348.36M-622.84M-736.54M
Treasury Stock-431K00000000
Accumulated OCI-1K-31K65K7K-712K-2.87M562K812K2.27M
Minority Interest000000000

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-12.22M-27.62M-39.31M55.46M-55.78M-87.17M-115.22M-247.58M-71.1M
Operating CF Margin %---283.87%-199.63%-171.16%-492.73%-3536.91%-32.51%
Operating CF Growth %--125.95%-42.34%241.08%-200.57%-56.29%-32.18%-114.87%71.28%
Net Income-11.86M-34.35M-41.98M-34.49M-49.76M-58.66M-112.96M-274.48M0
Depreciation & Amortization391K886K1.25M1.38M1.73M2.1M4.01M3.83M0
Stock-Based Compensation136K950K2.17M3.61M8.24M11.63M18.49M34.75M0
Deferred Taxes-27K-873K0000000
Other Non-Cash Items-2.43M4.11M-467K562K1.83M-695K-11.55M-23.23M-72.97M
Working Capital Changes1.56M1.65M-284K84.41M-17.81M-41.55M-13.21M11.55M1.87M
Change in Receivables000-1.88M774K892K193K15K0
Change in Inventory0002.29M3.79M0000
Change in Payables254K322K-195K225K1.17M1.86M2.63M8.28M2.7M
Cash from Investing+-8.93M-63.18M2.27M-146.24M-69.67M-33.4M-158.46M-502.56M69.98M
Capital Expenditures-1.76M-1.71M-1.35M-493K-2.64M-3.44M-2.37M-3.86M-2.37M
CapEx % of Revenue---2.52%9.46%6.76%10.13%55.1%1.08%
Acquisitions00-8K-18K67.02M33.4M000
Investments---------
Other Investing008K18K-67.02M-33.4M000
Cash from Financing+17.49M105.38M50.61M128.75M145.45M97.17M362.72M677.55M29.78M
Debt Issued (Net)000000000
Equity Issued (Net)1000K1000K1000K1000K1000K1000K1000K1000K1000K
Dividends Paid000000000
Share Repurchases000000000
Other Financing226K20K289K1.52M2.2M2.2M10.77M13.92M0
Net Change in Cash-3.66M14.58M13.56M37.97M20.01M-23.41M89.04M-72.59M28.45M
Free Cash Flow+-13.98M-29.33M-40.67M54.97M-58.42M-90.62M-117.59M-251.44M-73.47M
FCF Margin %---281.35%-209.09%-177.92%-502.85%-3592.01%-33.59%
FCF Growth %--109.77%-38.66%235.17%-206.28%-55.11%-29.77%-113.82%70.78%
FCF per Share-0.98-2.06-2.012.22-1.66-2.19-2.04-3.08-0.83
FCF Conversion (FCF/Net Income)1.03x0.80x0.94x-1.61x1.12x1.49x1.02x0.90x0.63x
Interest Paid099K91K82K71K0000
Taxes Paid01K1K1K4K0000

Key Ratios

Metric201720182019202020212022202320242025
Return on Equity (ROE)---163.16%-23.1%-19.91%-18.02%-23.28%-32.67%-10.92%
Return on Invested Capital (ROIC)---1818.36%-25.73%-21.69%-18.79%-26.84%-33.57%-12.37%
Gross Margin---92.93%93.83%95.87%82.86%45.23%97.9%
Net Margin----176.55%-178.1%-115.17%-483.05%-3921.1%-51.99%
Debt / Equity--0.07x0.03x0.02x0.01x0.00x0.02x0.03x
FCF Conversion1.03x0.80x0.94x-1.61x1.12x1.49x1.02x0.90x0.63x
Revenue Growth----43.01%82.28%-54.08%-70.07%3024.43%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.